Proteomic analysis of lymphoid and haematopoietic neoplasms: there's more than biomarker discovery.
Lymphoid and haematopoietic neoplasms comprise a broad spectrum of different tumours, classified by the World Health Organization (WHO) on the basis of a combination of morphology, immunophenotypic, genetic and clinical features. Up to date for many of these neoplasms no single feature is regarded as a diagnostic gold standard. The application of proteomics to the study of neoplastic haematological diseases could help in the search for new diagnostic and prognostic markers, as well as in the development of new therapeutic strategies. In this review, we focus on the actual role of proteomics technologies in the study of neoplastic haematology. In particular, we analyse the results obtained in the field of body fluid, cell lines, and tissues proteomics, and discuss the improvement allowed by the new developed proteomic strategies, such as nanofluidic systems, analysis of formalin-fixed tissues, and quantitative high throughput techniques (SILAC, ICAT, iTRAQ).